The biology of depression in cancer and the relationship between depression and cancer progression

International Review of Psychiatry

Volumn 26, Issue 1, 2014, Pages 16-30

  Sotelo, Jorge Luis ^a   Musselman, Dominique ^b   Nemeroff, Charles ^a,b  

^a UNIVERSITY OF MIAMI HOSPITAL   (United States)

^b JACKSON MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIDEPRESSANT AGENT; CYTOKINE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; DATA BASE; DEPRESSION; HUMAN; INFLAMMATION; MEDLINE; NEOPLASM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STRESS; TREATMENT RESISTANT DEPRESSION; CHEMICALLY INDUCED; COMPLICATION; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DISEASE COURSE; NEOPLASMS; PSYCHOLOGY;

DEPRESSION; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DISEASE PROGRESSION; HUMANS; INFLAMMATION; NEOPLASMS;

EID: 84896818201     PISSN: 09540261     EISSN: 13691627     Source Type: Journal    
DOI: 10.3109/09540261.2013.875891     Document Type: Article

References (176)

1. Abercrombie, H.C., Giese-Davis, J., Sephton, S., Epel, E.S., Turner-Cobb, J.M. & Spiegel, D. (2004). Flattened cortisol rhythms in metastatic breast cancer patients. Psychoneuroendocrinology, 29, 1082-1092
2. Besedovsky, H., del Rey, A., Sorkin, E. & Dinarello, C.A. (1986). Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science, 233, 652-654
3. Bierhaus, A., Wolf, J., Andrassy, M., Rohleder, N., Humpert, P.M., Petrov, D., Nawroth, P.P. (2003). A mechanism converting psychosocial stress into mononuclear cell activation. Proceedings of the National Academy of Sciences of the United States of America, 100, 1920-1925
4. Bower, J.E., Ganz, P.A., Aziz, N. & Fahey, J.L. (2002). Fatigue and proinfl ammatory cytokine activity in breast cancer survivors. Psychosomatic Medicine, 64, 604-611
5. Bower, J.E., Ganz, P.A., Dickerson, S.S., Petersen, L., Aziz, N. & Fahey, J.L. (2005). Diurnal cortisol rhythm and fatigue in breast cancer survivors. Psychoneuroendocrinology, 30, 92-100
6. Bower, J.E., Ganz, P.A., Irwin, M.R., Arevalo, J.M. & Cole, S.W. (2011). Fatigue and gene expression in human leukocytes: Increased NF-kappa B and decreased glucocorticoid signaling in breast cancer survivors with persistent fatigue. Brain, Behavior and Immunity, 25, 147-150
7. Bower, J.E., Ganz, P.A., Tao, M.L., Hu, W., Belin, T.R., Sepah, S., Aziz, N. (2009). Infl ammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer. Clinical Cancer Research, 15, 5534-5540
8. Braunstein, S., Formenti, S.C. & Schenider, R.J. (2008). Acquisition of stable inducible up-regulation of nuclear factorkappa B by tumor necrosis factor exposure confers increased radiation resistance without increased transformation in breast cancer cells. Molecular Cancer Research, 6, 78-88
9. Brown, D.W., Anda, R.F., Tiemeier, H., Felitti, V.J., Edwards, V.J., Croft, J.B. & Giles, W.H. (2009). Adverse childhood experiences and the risk of premature mortality. American Journal of Preventive Medicine, 37, 389-396
10. Bufalino, C., Hepgul, N., Aguglia, E. & Pariante, C.M. (2012). The role of immune genes in the association between depression and infl ammation: A review of recent clinical studies. Brain, Behavior and Immunity, 31, 31-47
11. Bull, S.J., Huezo-Diaz, P., Binder, E.B., Cubells, J.F., Ranjith, G., Maddock, C., Pariante, C.M. (2009). Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-Alpha and ribavirin treatment. Molecular Psychiatry, 14, 1095-1104
12. Capuron, L. & Dantzer, R. (2003). Cytokines and depression: The need for a new paradigm. Brain, Behavior and Immunity, 17, S19-24
13. Capuron, L., Fornwalt, F.B., Knight, B.T., Harvey, P.D., Ninan, P.T & Miller, A.H. (2009). Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals? Journal of Affective Disorders, 199, 181-185
14. Capuron, L., Gumnick, J.F., Musselman, D.L., Lawson, D.H., Reemsnyder, A., Nemeroff, C.B. & Miller, A.H. (2002a). Neurobehavioral effects of interferon-Alpha in cancer patients: Phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology, 26, 643-652
15. Capuron, L., Ravaud, A., Neveu, P.J., Miller, A.H., Maes, M. & Dantzer, R. (2002b). Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Molecular Psychiatry, 7, 468-473
16. Capuron, L., Raison, C.L., Musselman, D.L., Lawson, D.H., Nemeroff, C.B. & Miller, A.H. (2003a). Association of exaggerated HPA axis response to the initial injection of interferon-Alpha with development of depression during interferon-Alpha therapy. American Journal of Psychiatry, 160, 1342-1345
17. Capuron, L., Neurauter, G., Musselman, D.L., Lawson, D.H., Nemeroff, C.B., Fuchs, D. & Miller, A.H. (2003b). Interferon-Alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biological Psychiatry, 54, 906-914
18. Carney, R.M., Freedland, K.E., Stein, P.K., Miller, G.E., Steinmeyer, B., Rich, M.W. & Duntley, S.P. (2007). Heart rate variability and markers of infl ammation and coagulation in depressed patients with coronary heart disease. Journal of Psychosomatic Research, 62, 463-467
19. Carpenter, L.L., Gawuga, C.E., Tyrka, A.R., Lee, J.K., Anderson, G.M. & Price, L.H. (2010). Association between plasma IL-6 response to acute stress and early-life adversity in healthy adults. Neuropsychopharmacology, 35, 2617-2623
20. Cole, S.W. (2009). Chronic infl ammation and breast cancer recurrence. Journal of Clinical Oncology, 27, 3418-3419
21. Costa, D., Mogos, I. & Toma, T. (1985). Effi cacy and safety of mianserin in the treatment of depression of women with cancer. Acta Psychiatrica Scandinavica Supplementum, 320, 85-92
22. Courtier, N., Gambling, T., Enright, S., Barrett-Lee, P., Abraham, J. & Mason, M.D. (2013). Psychological and immunological characteristics of fatigued women undergoing radiotherapy for early stage breast cancer. Supportive Care in Cancer, 21, 173-181
23. Currier, M.B. & Nemeroff, C.B. (2014). Depression as a risk factor for cancer: From pathophysiological advances to treatment implications. Annual Review of Medicine, 65, 9.1-9.19. doi: 10.1146/annurev-med-061212-171507
24. Curzon, G. (1975). CSF homovanillic acid: An index of dopaminergic activity. Advances in Neurology, 9, 349-357
25. Danese, A., Moffi tt, T.E., Pariante, C.M., Ambler, A., Poulton, R. & Caspi, A. (2008). Elevated infl ammation levels in depressed adults with a history of childhood maltreatment. Archives of General Psychiatry, 65, 409-415
26. Danese, A., Pariante, C.M., Caspi, A., Taylor, A. & Poulton, R. (2007). Childhood maltreatment predicts adult infl ammation in a life-course study. Proceedings of the National Academy of Sciences of the United States of America, 104, 1319-1324.
27. Dantzer, R. (2001). Cytokine-induced sickness behavior: Mechanisms and implications. Annals of the New York Academy of Sciences, 933, 222-234
28. Dantzer, R., O Connor, J.C., Freund, G.G., Johnson, R.W. & Kelley, K.W. (2008). From infl ammation to sickness and depression: When the immune system subjugates the brain. Nature Reviews, Neuroscience, 9, 46-56
29. De Paiva, V.N., Lima, S.N., Fernandes, M.M., Soncini, R., Andrade, C.A., Giusti-Paiva, A. (2010). Prostaglandins mediate depressive-like behavior induced by endotoxin in mice. Behavioural Brain Research, 215, 146-151
30. Di Donato, J.A., Mercurio, F. & Karin, M. (2012). NF-kappa B and the link between infl ammation and cancer. Immunological Reviews, 246, 379-400
31. Di Padova, F., Pozzi, C., Tondre, M.J. & Tritapepe, R. (1991). Selective and early increase of IL-1 inhibitors, IL-6 and cortisol after elective surgery. Clinical and Experimental Immunology, 85, 137-142
32. Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E.K. & Lanctot, K.L. (2010). A meta-Analysis of cytokines in major depression. Biological Psychiatry, 67, 446-457
33. Dunn, A.J., Wang, J. & Ando, T. (1999). Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress. Advances in Experimental Medicine and Biology, 461, 117-1127
34. Eisenberger, N.I., Berkman, E.T., Inagaki, T.K., Ramseson, L.T., Mashal, N.M. &, Irwin, M.R. (2010a). Infl ammation-induced anhedonia: Endotoxin reduces ventral striatum responses to reward. Biological Psychiatry, 68, 748-754
35. Eisenberger, N.I., Inagaki, T.K., Rameson, L.T., Mashal, N.M. & Irwin, M.R. (2009). An fMRI study of cytokine-induced depressed mood and social pain: The role of sex differences. Neuroimage, 47, 881-890
36. Evans, D.L., McCartney, C.F., Haggerty, J.J. Jr, Nemeroff, C.B., Golden, R.N., Simon, J.B., Mason, G.A. (1988). Treatment of depression in cancer patients is associated with better life adaptation: A pilot study. Psychosomatic Medicine, 50, 73-76
37. Falagas, M.E., Zarkadoulia, E.A., Ioannidou, E.N., Peppas, G., Christodoulou, C. & Rafailidis, P.I. (2007). The effect of psychosocial factors on breast cancer outcome: A systematic review. Breast Cancer Research, 9, R44
38. Faller, H., B ülzebruck, H., Drings, P. & Lang, H. (1999). Coping, distress, and survival among patients with lung cancer. Archives of General Psychiatry, 56, 756-762
39. Fallowfi eld, L.J. (1990). Psychosocial adjustment after treatment for early breast cancer. Oncology (Williston Park, NY), 4, 89-97 ; discussion, 97-98
40. Fann, J.R., Thomas-Rich, A.M., Katon, W.J., Cowley, D., Pepping, M., McGregor, B.A. & Gralow, J. (2008). Major depression after breast cancer: A review of epidemiology and treatment. General Hospital Psychiatry, 30, 112-126
41. Fawzy, F.I., Fawzy, N.W., Hyun, C.S., Elashoff, R., Guthrie, D., Fahey, J.L. & Morton, D.L. (1993). Malignant melanoma. Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Archives of General Psychiatry, 50, 681-689
42. Fawzy, F.I., Cousins, N., Fawzy, N.W., Kemeny, M.E., Elashoff, R. & Morton, D. (1990a). A structured psychiatric intervention for cancer patients. I. Changes over time in methods of coping and affective disturbance. Archives of General Psychiatry, 47, 720-725
43. Fawzy, F.I., Kemeny, M.E., Fawzy, N.W., Elashoff, R., Morton, D., Cousins, N. & Fahey, J.L. (1990b). A structured psychiatric intervention for cancer patients. II. Changes over time in immunological measures. Archives of General Psychiatry, 47, 729-735
44. Filipski, E. & Levi, F. (2009). Circadian disruption in experimental cancer processes. Integrative Cancer Therapies, 8, 298-302
45. Fitzgerald, P., O Brien, S.M., Scully, P., Rijkers, K., Scott, L.V. & Dinan, T.G. (2006). Cutaneous glucocorticoid receptor sensitivity and proinfl ammatory cytokine levels in antidepressant-resistant depression. Psychological Medicine, 36, 37-43
46. Frasure-Smith, N., Lesperance, F., Irwin, M.R., Talajic, M. & Pollock, B.G. (2009). The relationship among heart rate variability, infl ammatory markers and depression in coronary heart disease patients. Brain, Behavior, and Immunity, 23, 1140-1147
47. Giese-Davis, J., Collie, K., Rancourt, K.M., Neri, E., Kraemer, H.C. & Spiegel, D. (2011). Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: A secondary analysis. Journal of Clinical Oncology, 29, 413-420
48. Greenberg, D.B., Gray, J.L., Mannix, C.M., Eisenthal, S. & Carey, M. (1993). Treatment-related fatigue and serum interleukin-1 levels in patients during external beam irradiation for prostate cancer. Journal of Pain and Symptom Management, 8, 196-200
49. Hernandez-Vargas, H., Rodriguez-Pinilla, S.M., Julian-Tendero, M., Sanchez Rovira, P., Cuevas, C., Anton, A., Moreno-Bueno, G. (2007). Gene expression profi ling of breast cancer cells in response to gemcitabine: NF-| B pathway activation as a potential mechanism of resistance. Brain Cancer Research and Treatment, 102, 157-172
50. Holland, J.C., Romano, S.J., Heiligenstein, J.H., Tepner, R.G., Wilson, M.G. (1998). A controlled trial of fl uoxetine and desipramine in depressed women with advanced cancer. Psychooncology, 7, 291-300
51. Holsboer, F. & Barden, N. (1996). Antidepressants and hypothalamic-pituitary-Adrenocortical regulation. Endocrine Reviews, 17, 187-205
52. Irwin, M.R., Olmstead, R., Valladares, E.M., Breen, E.C. & Ehlers, C.L. (2009). Tumor necrosis factor antagonism normalizes rapid eye movement sleep in alcohol dependence. Biological Psychiatry, 66, 191-195
53. Irwin, M.R., Wang, M., Ribeiro, D., Cho, H.J., Olmstead, R., Breen, E.C., Cole, S. (2008). Sleep loss activates cellular infl ammatory signaling. Biological Psychiatry, 64, 538-540
54. Jakeways, M.S., Mitchell, V., Hashim, I.A., Chadwick, S.J., Shenkin, A., Green, C.J. & Carli, F. (1994). Metabolic and infl ammatory responses after open or laparoscopic cholecystectomy . British Journal of Surgery, 81, 127-131
55. Jeannin, P., Duluc, D. & Delneste, Y. (2011). IL-6 and leukemia inhibitory factor are involved in the generation of tumorassociated macrophage: Regulation by IFN-gamma. Immunotherapy, 3, 23-26
56. Jehn, C.F., Kuhnhardt, D., Bartholomae, A., Pfeiffer, S., Schmid, P., Possinger, K., Luftner, D. (2010). Association of IL-6, hypothalamic-pituitary- Adrenal axis function, and depression in patients with cancer. Integrative Cancer Therapies, 9, 270-275
57. Johnson, J.D., Campisi, J., Sharkey, C.M., Kennedy, S.L., Nickerson, M., Greenwood, B.N. & Fleshner, M. (2005). Catecholamines mediate stress-induced increases in peripheral and central infl ammatory cytokines. Neuroscience, 135, 1295-1307
58. Juengling, F.D., Ebert, D., Gut, O., Engelbrecht, M.A., Rasenack, J., Nitzsche, E.U., Lieb, K. (2000). Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology, 152, 383-389
59. Kent, S., Bluthe, R.M., Kelley, K.W. & Dantzer, R. (1992). Sickness behavior as a new target for drug development. Trends in Pharmacological Sciences, 13, 24-28
60. Kiecolt-Glaser, J.K. & Glaser, R. (2002). Depression and immune function: Central pathways to morbidity and mortality. Journal of Psychosomatic Research, 53, 873-876
61. Koenig, H.G., Shelp, F., Goli, V., Cohen, H.J. & Blazer, D.G. (1989). Survival and health care utilization in elderly medical inpatients with major depression. Journal of the American Geriatrics Society, 37, 599-606
62. Koenig, H.G., Cohen, H.J., Blazer, D.G., Meador, K.G. & Westlund, R. (1992). A brief depression scale for use in the medically ill. International Journal of Psychiatry in Medicine, 22, 183-195
63. Koo, J.W. & Duman, R.S. (2009). Interleukin-1 receptor null mutant mice show decreased anxiety-like behavior and enhanced fear memory. Neuroscience Letters, 456, 39-43
64. Krishnan, R., Cella, D., Leonardi, C., Papp, K., Gottlieb, A.B., Dunn, M., Jahreis, A. (2007). Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque plaque psoriasis for up to 96 weeks. British Journal of Dermatology, 157, 1275-1277
65. Kristiansson, M., Saraste, L., Soop, M., Sundqvist, K.G. & Th ö rne, A. (1999). Diminished interleukin-6 and C-reactive protein responses to laparoscopic versus open cholecystectomy . Acta Anaesthesiologica Scandinavica, 43, 146-152
66. Kruimel, J.W., Pesman, G.J., Sweep, C.G., van der Vliet, J.A., Liem, T., Jansen, J., Naber, A.H. (1999). Depression of plasma levels of cytokines and ex-vivo cytokine production in relation to the activity of the pituitary-Adrenal axis, in patients undergoing major vascular surgery. Cytokine, 11, 382-388
67. Kudoh, A., Katagai, H. & Takazawa, T. (2001). Plasma infl ammatory cytokine response to surgical trauma in chronic depressed patients. Cytokine, 13, 104-108
68. Lamkin, D.M., Lutgendorf, S.K., Lubaroff, D., Sood, A.K., Beltz, T.G. & Johnson, A.K. (2011). Cancer induces infl ammation and depressive-like behavior in the mouse: Modulation by social housing. Brain, Behavior, and Immunity, 25, 555-564
69. Lane, D., Matte, I., Rancourt, C. & Piche, A. (2011). Prognostic signifi cance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer, 11, 210
70. Lanquillon, S., Krieg, J.C., Bening-Abu-Shach, U. & Vedder, H. (2000). Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology, 22, 370-379
71. Lestage, J., Verrier, D., Palin, K. & Dantzer, R. (2002). The enzyme indoleamine 2,3-dioxygenase is induced in the mouse brain in response to peripheral administration of lipopolysaccharide and superantigen. Brain, Behavior, and Immunity, 16, 596-601
72. Li, H., Ruan, X.Z., Powis, S.H., Fernando, R., Mon, W.Y., Wheeler, D.C., Varghese, Z. (2005). EPA and DHA reduce LPS-induced infl ammation responses in HK-2 cells: Evidence for a PPAR-gamma-dependent mechanism. Kidney International, 67, 867-874
73. Liebau, C., Merk, H., Schmidt, S., Roesel, C., Karreman, C., Prisack, J.B., Baltzer, A.W. (2002). Interleukin-12 and interleukin-18 change ICAM-I expression, and enhance natural killer cell mediated cytolysis of human osteosarcoma cells. Cytokines, Cellular and Molecular Therapy, 7, 135-142
74. Lin, P.Y., Huang, S.Y. & Su, K.P. (2010). A meta-Analytic review of polyunsaturated fatty acid compositions in patients with depression. Biological Psychiatry, 68, 140-147
75. Lindqvist, D., Janelidze, S., Hagell, P., Erhardt, S., Samuelsson, M., Minthon, L., Brundin, L. (2009). Interleukin-6 is elevated in the cerebrospinal fl uid of suicide attempters and related to symptom severity. Biological Psychiatry, 66, 287-292.
76. Liu, L., Mills, P.J., Rissling, M., Fiorentino, L., Natarajan, L., Dimsdale, J.E., Ancoli-Israel, S. (2012a). Fatigue and sleep quality are associated with changes in infl ammatory markers in breast cancer patients undergoing chemotherapy. Brain, Behavior, and Immunity, 26, 706-713
77. Liu, L., Rissling, M., Natarajan, L., Fiorentino, L., Mills, P.J., Dimsdale, J.E., Ancoli-Israel S. (2012b). The longitudinal relationship between fatigue and sleep in breast cancer patients undergoing chemotherapy. Sleep, 35, 237-245
78. Loprinzi, C.L., Kugler, J.W., Sloan, J.A., Mailliard, J.A., LaVasseur, B.I., Barton, D.L., Christensen, B.J. (2000). Venlafaxine in management of hot fl ashes in survivors of breast cancer: A randomised controlled trial. Lancet, 356, 2059-2063
79. Loprinzi, C.L., Sloan, J.A., Perez, E.A., Quella, S.K., Stella, P.J., Mailliard, J.A., Rummans T.A. (2002). Phase III evaluation of fl uoxetine for treatment of hot fl ashes. Journal of Clinical Oncology, 20, 1578-1583
80. Lutgendorf, S.K., Weinrib, A.Z., Penedo, F., Russell, D., DeGeest, K., Costanzo, E.S., Lubaroff, D.M. (2008). Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. Journal of Clinical Oncology, 26, 4820-4827
81. Madhusudan, S., Foster, M., Muthuramalingam, S.R., Braybrooke, J.P., Wilner, S., Kaur, K., Harris, A.L. (2004). A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clinical Cancer Research, 10, 6528-6534
82. Madhusudan, S., Muthuramalingam, S.R., Braybrooke, J.P., Wilner, S., Kaur, K., Han, C., Ganesan, T.S. (2005). Study of etanercept, a tumor necrosis alpha inhibitor, in recurrent ovarian cancer. Journal of Clinical Oncology, 23, 5950-5959
83. Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. (2008). Cancer-related infl ammation. Nature, 454, 436-444
84. Massie, M.J. (2004). Prevalence of depression in patients with cancer. Journal of the National Cancer Institute Monographs, 32, 57-71
85. Mathias, S.D., Colwell, H.H., Miller, D.P., Moreland, L.W., Buatti, M. & Wanke, L. (2000). Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. Clinical Therapeutics, 22, 128-139
86. Max, M.B., Lynch, S.A., Muir, J., Shoaf, S.E., Smoller, B. & Dubner, R. (1992). Effects of desipramine, amitriptyline, and fl uoxetine on pain in diabetic neuropathy. New England Journal of Medicine, 326, 1250-1256
87. Mazzeo, R.S., Donovan, D., Fleshner, M., Butterfield, G.E., Zamudio, S., Wolfel, E.E. & Moore, L.G. (2001). Interleukin-6 response to exercise and high-Altitude exposure: Infl uence of alpha-Adrenergic blockade. Journal of Applied Physiology, 91, 2143-2149
88. McDaniel, J.S., Musselman, D.L., Porter, M.R., Reed, D.A. & Nemeroff, C.B. (1995). Depression in patients with cancer. Diagnosis, biology, and treatment. Archives of General Psychiatry, 52, 89-99
89. McGee, R., Williams, S. & Elwood, M. (1994). Depression and the development of cancer: A meta-Analysis. Social Science and Medicine, 38, 187-192
90. McKenna, M.C., Zevon, M.A., Corn, B. & Rounds, J. (1999). Psychosocial factors and the development of breast cancer: A meta-Analysis. Health Psychology, 18, 520-531
91. Mehta, D., Raison, C.L., Woolwine, B.J., Haroon, E., Binder, E.B., Miller, A.H. & Felger, J.C. (2013). Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infl iximab in patients with treatment-resistant depression. Brain, Behavior, and Immunity, 31, 205-215
92. Melhem, A., Yamada, S.D., Fleming, G.F., Delgado, B., Brickley, D.R., Wu, W., Conzen, S.D. (2009). Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-Apoptotic genes SGK1 and MKP1/DUSP1 in ovarian tissues. Clinical Cancer Research, 15, 3196-3204
93. Mendlewicz, J., Kriwin, P., Oswald, P., Souery, D., Alboni, S. & Brunello, N. (2006). Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: A pilot open label study. International Clinical Psychopharmacology, 21, 227-231
94. Merali, Z., Du, L., Hrdina, P., Palkovits, M., Faludi, G., Poulter, M.O. & Anisman, H. (2004). Dysregulation in the suicide brain: MRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical region. Journal of Neuroscience, 24, 1478-1485
95. Meyers, C.A., Albitar, M. & Estey, E. (2005). Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer, 104, 788-793
96. Miller, A.H., Ancoli-Israel, S., Bower, J.E., Capuron, L. & Irwin, M.R. (2008). Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. Journal of Clinical Oncology, 26, 971-982
97. Miller, A.H., Maletic, V. & Raison, C.L. (2009). Infl ammation and its discontents: The role of cytokines in the pathophysiology of major depression. Biological Psychiatry, 65, 732-741
98. Mills, P.J., Ancoli-Israel, S., Parker, B., Natarajan, L., Hong, S., Jain, S., von K ä nel, R. (2008). Predictors of infl ammation in response to anthracycline-based chemotherapy for breast cancer. Brain, Behavior, and Immunity, 22, 98-104
99. Mills, P.J. & Dimsdale, J.E. (2004). Sleep apnea: A model for studying cytokines, sleep, and sleep disruption. Brain, Behavior, and Immunity, 18, 298-303
100. Mizoi, Y., Kaneko, H., Oharazawa, A. & Kuroiwa, H. (1997). Parkinsonism in a patient receiving interferon alpha therapy for chronic hepatitis C. [in Japanese]. Rinsho Shinkeigaku, 37, 54-56
101. Monk, J.P., Phillips, G., Waite, R., Kuhn, J., Schaaf, L.J., Otterson, G.A., Villalona-Calero, M.A. (2006). Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. Journal of Clinical Oncology, 24, 1852-1859
102. Mormont, M.C. & Levi, F. (1997). Circadian-system alterations during cancer processes: A review. International Journal of Cancer, 70, 241-247
103. Motivala, S.J., Sarfatti, A., Olmos, L. & Irwin, M.R. (2005). Infl ammatory markers and sleep disturbance in major depression. Psychosomatic Medicine, 67, 187-194
104. Muller, N., Schwarz, M.J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Muller, B., Riedel, M. (2006). The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: Results of a double-blind, randomized, placebocontrolled, add-on pilot study to reboxetine. Molecular Psychiatry, 11, 680-684
105. Murumkar, P.R., DasGupta, S., Chandani, S.R., Giridhar, R. & Yadav, M.R. (2010). Novel TACE inhibitors in drug discovery: A review of patented compounds. Expert Opinion on Therapeutic Patents, 20, 31-57
106. Musselman, D.L., Lawson, D.H., Gumnick, J.F., Manatunga, A.K., Penna, S., Goodkin, R.S., Miller, A.H. (2001a). Paroxetine for the prevention of depression induced by high-dose interferon alfa. New England Journal of Medicine, 344, 961-966
107. Musselman, D.L., Miller, A.H., Porter, M.R., Manatunga, A., Gao, F., Penna, S., Nemeroff, C.B. (2001b). Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: Preliminary fi ndings. American Journal of Psychiatry, 158, 1252-1257
108. Musselman, D.L., Roysrer, E.B., Wang, M., Long, Q., Trimble, L.M., Mann, T.K., Miller, A.H. (2013). The impact of escitalopram on IL-2-induced neuroendocrine, immune, and behavioral changes in patients with malignant melanoma: Preliminary fi ndings. Neuropsychopharmacology, 38 (10), 1921-1928. doi:10.1038/npp.2013.85
109. Nicolson, S.E., Miller, A.H., Lawson, D. & Musselman, D.L. (2006). Neuropsychiatric effects of IL-2: Mechanisms and treatment implications. Depression: Mind and Body, 2, 120-129
110. Nilsson, M.B., Langley, R.R. & Fidler, I.J. (2005). Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Research, 65, 10794-10800
111. Obata, N.H., Tamakoshi, K., Shibata, K., Kikkawa, F. & Tomoda, Y. (1997). Effects of interleukin-6 on in vitro cell attachment, migration, and invasion of human ovarian carcinoma. Anticancer Research, 17, 337-342
112. Offner, F.A., Obrist, P., Stadlmann, S., Feichtinger, H., Klinger, P., Herold, M., Marth, C. (1995). IL-6 secretion by human peritoneal mesothelial and ovarian cancer cells. Cytokine, 7, 542-547
113. Omne-Pont é n, M., Holmberg, L., Burns, T., Adami, H.O. & Bergstr ö m, R. (1992). Determinants of the psycho-social outcome after operation for breast cancer. Results of a prospective comparative interview study following mastectomy and breast conservation. European Journal of Cancer, 28A, 1062-1067
114. Owens, M.J. & Nemeroff, C.B. (1991). Physiology and pharmacology of corticotropin-releasing factor. Pharmacological Reviews, 43, 425-473
115. Owens, M.J. & Nemeroff, C.B. (1993). The role of corticotropinreleasing factor in the pathophysiology of affective and anxiety disorders: Laboratory and clinical studies. Ciba Foundation Symposium, 172, 296-308; discussion, 308-316
116. Pace, T.W., Mletzko, T.C., Alagbe, O., Musselman, D.L., Nemeroff, C.B., Miller, A.H. & Heim, C.M. (2006). Increased stress-induced infl ammatory responses in male patients with major depression and increased early life stress. American Journal of Psychiatry, 163, 1630-1633
117. Pagnoni, G., Zink, C.F., Montague, P.R. & Berns, G.S. (2002). Activity in human ventral striatum locked to errors of reward prediction. Nature Neuroscience, 5, 97-98
118. Palesh, O., Zeitzer, J.M., Conrad, A., Giese-Davis, J., Mustian, K.M., Popek, V., Spiegel, D. (2008). Vagal regulation, cortisol, and sleep disruption in women with metastatic breast cancer. Journal of Clinical Sleep Medicine, 4, 441-449
119. Pan, D., Kocherginsky, M. & Conzen, S.D. (2011). Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer. Cancer Research, 71, 6360-6370
120. Pang, D., Kocherginsky, M., Krausz, T., Kim, S.Y. & Conzen, S.D. (2006). Dexamethasone decreases xenograft response to paclitaxel through inhibition of tumor cell apoptosis . Cancer Biology and Therapy, 58, 933-940
121. Papanicolaou, D.A. (2000). Euthyroid sick syndrome and the role of cytokines. Reviews in Endocrine and Metabolic Disorders, 1, 43-48
122. Pariante, C.M. & Miller, A.H. (2001). Glucocorticoid receptors in major depression: Relevance to pathophysiology and treatment. Biological Psychiatry, 49, 391-404
123. Pelletier, G., Verhoef, M.J., Khatri, N. & Hagen, N. (2002). Quality of life in brain tumor patients: The relative contributions of depression, fatigue, emotional distress, and existential issues. Journal of Neurooncology, 57, 41-49
124. Pezzella, G., Moslinger-Gehmayr, R. & Contu, A. (2001). Treatment of depression in patients with breast cancer: A comparison between paroxetine and amitriptyline. Breast Cancer Research and Treatment, 70, 1-10
125. Pirl, W.F., Greer, J.A., Traeger, L., Jackson, V., Lennes, I.T., Gallagher, R., Temel, J.S. (2012). Depression and survival in metastatic non-small-cell lung cancer: Effects of early palliative care. Journal of Clinical Oncology, 30, 1310-1315
126. Plante, M., Rubin, S.C., Wong, G.Y., Federici, M.G., Finstad, C.L. & Gastl, G.A. (1994). Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer, 73, 1882-1888
127. Plotkin, S.R., Banks, W.A. & Kastin, A.J. (1996). Comparison of saturable transport and extracellular pathways in the passage of interleukin-1 alpha across the blood brain barrier. Journal of Neuroimmunology, 67, 41-47
128. Polsky, D., Doshi, J.A., Marcus, S., Oslin, D., Rothbard, A., Thomas, N. & Thompson, C.L. (2005). Long-Term risk for depressive symptoms after a medical diagnosis. Archives of Internal Medicine, 165, 1260-1266
129. Pyter, L.M., Pineros, V., Galang, J.A., McClintock, M.K. & Prendergast, B.J. (2009). Peripheral tumors induce depressive-like behaviors and cytokine production and alter hypothalamic-pituitary-Adrenal axis regulation. Proceedings of the National Academy of Sciences of the United States of America, 106, 9069-9074
130. Rae, M.T. & Hillier, S.G. (2005). Steroid signaling in the ovarian surface epithelium. Trends in Endocrinology and Metabolism, 16, 327-333
131. Raison, C.L., Borisov, A.S., Broadwell, S.D., Capuron, L., Woolwine, B.J., Jacobson, I.M., Miller, A.H. (2005a). Depression during pegylated interferon-Alpha plus ribavirin therapy: Prevalence and prediction. Journal of Clinical Psychiatry, 66, 41-48
132. Raison, C.L., Dantzer, R., Kelley, K.W., Lawson, M.A., Woolwine, B.J., Vogt, G., Miller AH. (2010). CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-Alpha: Relationship to CNS immune responses and depression. Molecular Psychiatry, 15, 393-403
133. Raison, C.L., Demetrashvii, M.F., Capuron, L. & Miller, A.H. (2005b). Neuropsychiatric adverse effects of interferon-Alpha: Recognition and management. CNS Drugs, 19, 105-123
134. Raison, C.L. & Miller, A.H. (2003). Depression in cancer: New developments regarding diagnosis and treatment. Biological Psychiatry, 54, 283-294
135. Raison, C.L., Woolwine, B.J., Demetrashvii, M.F., Borisov, A.S., Weinreib, R., Staab, J.P., Miller, A.H. (2007). Paroxetine for prevention of depressive symptoms induced by interferon-Alpha and ribavirin for hepatitis C. Alimentary Pharmacology and Therapeutics, 25, 1163-1174
136. Raison, C.L., Rutherford, R.E., Woolwine, B.J., Shuo, C. Schettler, P ., Miller, A.H. (2013). A randomized control trial of the tumor necrosis factor antagonist infl iximab for treatment-resistant depression: The role of baseline infl ammatory markers. JAMA Psychiatry, 70, 31-41
137. Razavi, D., Allilaire, J.F., Smith, M., Salimpour, A., Verra, M., Desclaux, B., Blin, P. (1996). The effect of fl uoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatrica Scandinavica, 94, 205-210
138. Rivest, S., Lacroix, S., Vallieres, L., Nadeau, S., Zhang, J. & Lafl amme, N. (2000). How the blood talks to the brain parenchyma and the paraventricular nucleus of the hypothalamus during systemic infl ammatory and infectious stimuli. Proceedings of the Society for Experimental Biology and Medicine, 223, 22-38
139. Rivier, C. (1995). Infl uence of immune signals on the hypothalamic-pituitary axis of the rodent. Frontiers in Neuroendocrinology, 16, 151-182
140. Rooney, A.G., McNamara, S., Mackinnon, M., Fraser, M., Rampling, R., Carson, A. & Grant, R. (2011). Frequency, clinical associations, and longitudinal course of major depressive disorder in adults with cerebral glioma. Journal of Clinical Oncol ogy, 29, 4307-4312
141. Roscoe, J.A., Morrow, G.R., Hickok, J.T., Mustian, K.M., Griggs, J.J., Matteson, S.E., Smith, B. (2005). Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Research Treatment, 89, 243-249
142. Ross, L., Boesen, E.H., Dalton, S.O. & Johansen, C. (2002). Mind and cancer: Does psychosocial intervention improve survival and psychological well-being? European Journal of Cancer, 38, 1447-1457
143. Sarasombath, P., Sumida, K. & Kaku, D.A. (2002). Parkinsonism associated with interferon alpha therapy for chronic myelogenous leukemia. Hawaii Medical Journal, 61 (3) : 48-57
144. Satin, J.R., Linden, W. & Phillips, M.J. (2009). Depression as a predictor of disease progression and mortality in cancer patients: A meta-Analysis. Cancer, 115, 5349-5361
145. Savas, S., Hyde, A., Stuckless, S.N., Parfrey, P., Banfi eld Younghusband, H. & Green, R. (2012). Serotonin transporter gene (SLC6A4) variations are associated with poor survival in colorectal cancer patients. PLOS ONE, 7, e38953
146. Scambia, G., Testa, U., Panici, P.B., Foti, E., Martucci, R., Gaducci, A., Mancuso, S. (1995). Prognostic signifi cance of interleukin 6 serum levels in patients with ovarian cancer. British Journal of Cancer, 71, 354-356
147. Schlossmacher, G., Stevens, A. & White, A. (2011). Glucocorticoid receptor-mediated apoptosis: Mechanisms of resistance in cancer cells. Journal of Endocrinology, 211, 17-25
148. Schrepf, A., Clevenger, L., Christensen, D., DeGeest, K., Bender, D.,
149. Semenchuk, M.R., Sherman, S. & Davis, B. (2001). Doubleblind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology, 57, 1583-1588
150. Sephton, S.E., Sapolsky, R.M., Kraemer, H.C. & Spiegel, D. (2000). Diurnal cortisol rhythm as a predictor of breast cancer survival. Journal of the National Cancer Institute, 92, 994-1000
151. Simen, B.B., Duman, C.H., Simen, A.A. & Duman, R.S. (2006). TNF alpha signaling in depression and anxiety: Behavioral consequences of individual receptor targeting. Biological Psychiatry, 59, 775-785
152. Sluzewska, A., Sobieska, M. & Rybakowski, J.K. (1997). Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression. Neuropsychobiology, 35, 123-127
153. Spiegel, D., Bloom, J.R., Kraemer, H.C. & Gottheil, E. (1989). Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet, 2, 888-891
154. Stearns, V., Isaacs, C., Rowland, J., Crawford, J., Ellis, M.J., Kramer, R., Hayes, D.F. (2000). A pilot trial assessing the effi cacy of paroxetine hydrochloride (Paxil) in controlling hot fl ashes in breast cancer survivors. Annals of Oncology, 11, 17-22
155. Stommel, M., Given, B.A. & Given, C.W. (2002). Depression and functional status as predictors of death among cancer patients. Cancer, 94, 2719-2727
156. Stoudemire, A. & Thompson, T.L. II. (1983). Medication noncompliance: Systematic approaches to evaluation and intervention. General Hospital Psychiatry, 5, 233-239
157. Su, K.P., Huang, S.Y., Peng, C.Y., Lai, H.C., Huang, C.L., Chen, Y.C., Pariante, C.M. (2010). Phospholipase A2 and cyclooxygenase 2 genes infl uence the risk of interferonalpha-induced depression by regulating polyunsaturated fatty acids levels. Biological Psychiatry, 67, 550-557
158. Su, S., Zhao, J., Bremner, J.D., Miller, A.H. & Tang, W. (2009). Serotonin transporter gene, depressive symptoms, and interleukin-6. Circulation: Cadiovascular Genetics, 2 (6), 614-620
159. Sumpton, J.E. & Moulin, D.E. (2001). Treatment of neuropathic pain with venlafaxine. Annals of Pharmacotherapy, 35, 557-559
160. Sunami, M., Nishikawa, T., Yorogi, A. & Shimoda, M. (2000). Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-Alpha. Clinical Neuropharmacology, 23, 59-61
161. Teeling, J.L., Cunningham, C., Newman, T.A. & Perry, V.H. (2010). The effect of nonsteroidal anti-infl ammatory agents on behavioural changes and cytokine production following systemic infl ammation: Implications for a role of COX-1. Brain, Behavior, and Immunity, 24, 409-419
162. Thayer, J.F. & Fischer, J.E. (2009). Heart rate variability, overnight urinary norepinephrine and C-reactive protein: Evidence for the cholinergic anti-infl ammatory pathway in healthy human adults. Journal of Internal Medicine, 265, 439-447
163. Torres, M.A., Pace, T.W., Liu, T., Felger, J.C., Mister, D., Doho, G.H., Miller, A.H. (2013). Predictors of depression in breast cancer patients treated with radiation: Role of prior chemotherapy and nuclear factor kappa B. Cancer, 119, 1951-1959
164. Touitou, Y., Bogdan, A., Levi, F., Benavides, M. & Auzeby, A. (1996). Disruption of the circadian patterns of serum cortisol in breast and ovarian cancer patients: Relationships with tumour marker antigens. British Journal of Cancer, 748, 1248-1252
165. Tracey, K.J. (2009). Refl ex control of immunity. Nature Reviews Immunology, 9, 418-428
166. Tyring, S., Gottlieb, A., Papp, K., Gordon, K., Leonardi, C., Wang, A., Krishnan, R. (2006). Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomized phase III trial. Lancet, 367, 29-35
167. van Heeringen, K. & Zivkov, M. (1996). Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. British Journal of Psychiatry, 169, 440-443
168. Wang, X.S., Shi, Q., Williams, L.A., Mao, L., Cleeland, C.S., Komaki, R.R., Liao, Z. (2010). Infl ammatory cytokines are associated with the development of increased symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain, Behavior, and Immunity, 24, 968-974
169. Warner-Schmidt, J.L., Vanover, K.E., Chen, E.Y., Marshall, J.J. & Greengard, P. (2011). Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinfl ammatory drugs in mice and humans. Proceedings of the National Academy of Sciences of the United States of America, 108 (22), 9262-9267
170. Watkins, L.R., Goehler, L.E., Relton, J.K., Tartaglia, N., Silbert, L., Martin, D. & Maier, S.F. (1995). Blockade of interleukin-1 induced hyperthermia by subdiaphragmatic vagotomy: Evidence for vagal mediation of immune-brain communication. Neuroscience Letters, 183, 27-31
171. Watson, J.M., Sensintaffar, J.L., Berek, J.S. & Mart í nez-Maza, O. (1990). Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Research, 50, 6959-6965
172. Weinrib, A.Z., Sephton, S.E., DeGeest, K., Penedo, F., Bender, D., Zimmerman, B., Lutgendorf, S.K (2010). Diurnal cortisol dysregulation, functional disability, and depression in wemen with ovarian cancer Cancer, 116, 4410-4419
173. Wratten, C., Kilmurray, J., Nash, S., Seldon, M., Hamilton, C.S., O Brien, P.C., Denham, J.W (2004). Fatigue during breast radiotherapy and its relationship to biological facters International Journal of Radiation Oncology, Biology, Physics, 59, 160-167
174. Yirmiya, R., Weidenfeld, J., Pollak, Y., Morag, M., Morag, A., Avitsur, R., Ovadia, H (1999). Cytokines, depression due to a general medical condition ', and antieepressant drugs Advances in Experimental Medicine and Biology, 461, 283-316
175. Zebrack, B.J., Zeltzer, L.K., Whitton, J., Mertens, A.C., Odom, L., Berkow, R. & Robison, L.L. (2002). Psychological outcomes in long-Term survivors of childhood leukemia, Hodgkin s disease, and non-Hodgkin s lymphoma: A report from the Childhood Cancer Survivor Study. Pediatrics, 110, 42-52
176. Zorrilla, E.P., Luborsky, L., McKay, J.R., Rosenthal, R., Houldin, A., Tax, A., Schmidt, K. (2001). The relationship of depression and stressors to immunological assays: A metaanalytic review. Brain, Behavior, Immunity, 15, 199-226